Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
1,048 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07441694 | Study of INCA036978 in Participants With Myeloproliferative Neoplasms | recruiting | Phase 1 | 218 | Incyte CorporationINDUSTRY | 11 | Jul 22, 2026 | clinicaltrials |
| NCT07720284 | An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC(TU-04) | recruiting | Phase 3 | 915 | AstraZenecaINDUSTRY | 16 | Jul 22, 2026 | clinicaltrials |
| NCT04918186 | Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer(IPROC) | recruiting | Phase 2 | 60 | Canadian Cancer Trials GroupNETWORK | 2 | Jul 21, 2026 | clinicaltrials |
| NCT06520345 | The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global) | recruiting | Phase 3 | 520 | Telix Pharmaceuticals (Innovations) Pty LimitedINDUSTRY | 6 | Jul 21, 2026 | clinicaltrials |
| NCT07218809 | AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer(TREVI-OC-01) | recruiting | Phase 3 | 1,100 | AstraZenecaINDUSTRY | 24 | Jul 21, 2026 | clinicaltrials |
| NCT05432856 | Impact of Metabolic Health Patterns And Breast Cancer Over Time in Women(IMPACT-Women) | recruiting | N/A | 65 | University of AlbertaOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT06476808 | A Study to Evaluate the Safety, Tolerability, and Efficacy of Escalating Doses of BMS-986463 in Participants With Select Advanced Malignant Tumors. | recruiting | Phase 1 | 240 | Bristol-Myers SquibbINDUSTRY | 5 | Jul 20, 2026 | clinicaltrials |
| NCT07155226 | Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression(MOMENTUM) | recruiting | Phase 1 / Phase 2 | 84 | AstraZenecaINDUSTRY | 9 | Jul 20, 2026 | clinicaltrials |
| NCT05592938 | Partial Breast Re-irradiation Using Ultra Hypofractionation (PRESERVE)(PRESERVE) | recruiting | N/A | 171 | University Health Network, TorontoOTHER | 10 | Jul 17, 2026 | clinicaltrials |
| NCT06788990 | FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC(FORTIFI-HN01) | recruiting | Phase 2 / Phase 3 | 650 | Bicara TherapeuticsINDUSTRY | 26 | Jul 17, 2026 | clinicaltrials |
| NCT07252726 | Evaluating Dose Timing (Morning vs Evening) of Endocrine-based Therapies in Metastatic Breast and Prostate Cancers | recruiting | Phase 4 | 50 | Ottawa Hospital Research InstituteOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT06121843 | A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma | recruiting | Phase 1 | 187 | Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyINDUSTRY | 2 | Jul 16, 2026 | clinicaltrials |
| NCT06850766 | The Feasibility and Efficacy of Dose Timing (Morning vs Evening) of Temozolomide in the Treatment of Glioblastoma(TMZ-CHRONO) | recruiting | N/A | 50 | Ottawa Hospital Research InstituteOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT06948448 | A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer | recruiting | Phase 2 | 144 | Ono Pharmaceutical Co., Ltd.INDUSTRY | 6 | Jul 16, 2026 | clinicaltrials |
| NCT02343042 | Selinexor and Backbone Treatments of Multiple Myeloma Patients(STOMP) | recruiting | Phase 1 / Phase 2 | 300 | Karyopharm Therapeutics IncINDUSTRY | 2 | Jul 15, 2026 | clinicaltrials |
| NCT06937177 | Safely Optimizing Body Weight With Mifomelatide (TCMCB07) in Patients With Newly Diagnosed Colorectal Cancer (CRC) or Pancreatic Ductal Adenocarcinoma (PDAC) Undergoing Chemotherapy | recruiting | Phase 2 | 120 | Endevica BioINDUSTRY | 2 | Jul 15, 2026 | clinicaltrials |
| NCT07286266 | A Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01) | recruiting | Phase 3 | 450 | GlaxoSmithKlineINDUSTRY | 3 | Jul 15, 2026 | clinicaltrials |
| NCT07377747 | Prospective Study Evaluating the Treatment Outcomes for Localised Recurrent, Resectable Retroperitoneal Liposarcoma(ReLaPSe) | recruiting | — | 100 | Australia and New Zealand Sarcoma AssociationOTHER | 8 | Jul 15, 2026 | clinicaltrials |
| NCT07602777 | A Study Evaluating the Efficacy and Safety of Risvutatug Rezetecan in Participants With Advanced Sarcomas (EMBOLD Sarcoma-202) | recruiting | Phase 1 / Phase 2 | 113 | GlaxoSmithKlineINDUSTRY | 3 | Jul 15, 2026 | clinicaltrials |
| NCT05371808 | Economic Analysis of Early vs Delayed Therapy in Newly Diagnosed Asymptomatic High-Risk Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: | recruiting | — | 247 | Canadian Cancer Trials GroupNETWORK | 1 | Jul 14, 2026 | clinicaltrials |
| NCT05451004 | SPECT-CT Guided ELEctive Contralateral Neck Treatment for Patients With Lateralized Oropharyngeal Cancer(SELECT) | recruiting | Phase 3 | 510 | Canadian Cancer Trials GroupNETWORK | 2 | Jul 14, 2026 | clinicaltrials |
| NCT06205485 | Neoadjuvant Chemotherapy, Excision And Observation vs Chemoradiotherapy For Rectal Cancer(NEO-RT) | recruiting | Phase 3 | 250 | Canadian Cancer Trials GroupNETWORK | 2 | Jul 14, 2026 | clinicaltrials |
| NCT06592924 | Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response(TRIPLE-SWITCH) | recruiting | Phase 3 | 830 | Canadian Cancer Trials GroupNETWORK | 4 | Jul 14, 2026 | clinicaltrials |
| NCT06686771 | Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer(CURB2) | recruiting | Phase 3 | 320 | Canadian Cancer Trials GroupNETWORK | 2 | Jul 14, 2026 | clinicaltrials |
| NCT06942039 | Pilot Study of IT Topotecan and Maintenance Chemotherapy for HR-EBTs in Children < 6 Years, Post Consolidation | recruiting | Early Phase 1 | 15 | C17 CouncilOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT04792489 | DALY II USA/ MB-CART2019.1 for DLBCL | recruiting | Phase 2 | 315 | Miltenyi Biomedicine GmbHINDUSTRY | 2 | Jul 13, 2026 | clinicaltrials |
| NCT05650632 | A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma | recruiting | Phase 1 | 210 | AbbVieINDUSTRY | 7 | Jul 13, 2026 | clinicaltrials |
| NCT07109219 | Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia(ALLight) | recruiting | Phase 1 / Phase 2 | 83 | AstraZenecaINDUSTRY | 9 | Jul 13, 2026 | clinicaltrials |
| NCT07699328 | A Study of VRN110755 in Patients With EGFR-Mutant Non-Small Cell Lung Cancer(REACH-EGFR) | recruiting | Phase 1 / Phase 2 | 315 | Voronoi, IncINDUSTRY | 10 | Jul 13, 2026 | clinicaltrials |
| NCT04824014 | 4FMFES-PET Imaging of ER+ Advanced Breast Cancers | recruiting | Phase 2 | 150 | Centre de recherche du Centre hospitalier universitaire de SherbrookeOTHER | 1 | Jul 10, 2026 | clinicaltrials |
| NCT07694479 | Feasibility of a Habit-Based Intervention to Reduce Sedentary Behaviour in Cancer Survivors | recruiting | N/A | 30 | University of TorontoOTHER | 1 | Jul 10, 2026 | clinicaltrials |
| NCT07696637 | Access My Breast Cancer Care App | recruiting | N/A | 148 | University of British ColumbiaOTHER | 1 | Jul 10, 2026 | clinicaltrials |
| NCT04685616 | Brentuximab Vedotin in Early Stage Hodgkin Lymphoma(RADAR) | recruiting | Phase 3 | 1,042 | University College, LondonOTHER | 12 | Jul 8, 2026 | clinicaltrials |
| NCT05753618 | Evaluating Omission of Granulocyte Colony-stimulating Factors in Breast Cancer Patients Receiving Paclitaxel Portion of Dose-dense Adriamycin-cyclophosphamide and Paclitaxel Chemotherapy(REaCT-OGF) | recruiting | Phase 4 | 242 | Ottawa Hospital Research InstituteOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT06979180 | A Clinical Trial to Investigate the Safety and Efficacy of Papillex® on Abnormal Cervical Cells Caused by HPV. | recruiting | N/A | 60 | Papillex Inc.INDUSTRY | 1 | Jul 8, 2026 | clinicaltrials |
| NCT07509450 | Fecal Microbiota Transplantation in Patients Undergoing Chimeric Antigen Receptor T-cell Therapy and Allogeneic Stem Cell Transplant: A Pilot Study(FMT) | recruiting | N/A | 20 | University Health Network, TorontoOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT06183437 | The STOP-MED CTRCD Trial(STOP-MED CTRCD) | recruiting | Phase 4 | 335 | Dinesh ThavendiranathanOTHER | 6 | Jul 7, 2026 | clinicaltrials |
| NCT06217822 | First-in-human Study of 225Ac-PSMA-Trillium (BAY 3563254) in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC)(PAnTHA) | recruiting | Phase 1 | 198 | BayerINDUSTRY | 10 | Jul 7, 2026 | clinicaltrials |
| NCT06796907 | A Study of Mocertatug Rezetecan in Combination With Anti-cancer Therapies for Advanced Solid Tumors (BEHOLD-2) | recruiting | Phase 1 / Phase 2 | 305 | GlaxoSmithKlineINDUSTRY | 23 | Jul 7, 2026 | clinicaltrials |
| NCT06927635 | Stereotactic Body Radiotherapy or Standard of Care for Prostate Oligoprogressive Cancer(SECURE) | recruiting | Phase 2 | 75 | University Health Network, TorontoOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT04877522 | Asciminib Roll-over Study | recruiting | Phase 4 | 347 | Novartis PharmaceuticalsINDUSTRY | 29 | Jul 6, 2026 | clinicaltrials |
| NCT05074355 | Study of Venetoclax and Azacitidine in Advanced BCR-ABL Negative Myeloproliferative Neoplasms | recruiting | Phase 2 | 40 | University Health Network, TorontoOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT02560883 | Hairy Cell Leukemia Patient Data Registry(HCL-PDR) | recruiting | — | 5,000 | Ohio State University Comprehensive Cancer CenterOTHER | 3 | Jul 2, 2026 | clinicaltrials |
| NCT07081646 | A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis.(ALACRITY) | recruiting | Phase 1 / Phase 2 | 91 | Alexion Pharmaceuticals, Inc.INDUSTRY | 3 | Jul 2, 2026 | clinicaltrials |
| NCT04064060 | A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials | recruiting | Phase 3 | 665 | CelgeneINDUSTRY | 22 | Jul 1, 2026 | clinicaltrials |
| NCT06057402 | Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)(MagnetisMM15) | recruiting | Phase 4 | 80 | PfizerINDUSTRY | 7 | Jul 1, 2026 | clinicaltrials |
| NCT07098338 | A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)(LIBRA) | recruiting | Phase 2 | 278 | AstraZenecaINDUSTRY | 12 | Jul 1, 2026 | clinicaltrials |
| NCT07483658 | Non-inferiority Study Comparing Salvage Pelvic Radiotherapy in 25 Fractions (62.5 Gy/25) Versus 20 Fractions (52.5 Gy/20) for Recurrent Prostate Cancer After Surgery.(HYP-OP-RT) | recruiting | N/A | 434 | CHU de Quebec-Universite LavalOTHER | 1 | Jul 1, 2026 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials